Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | President & CCO | April 13, 2023 | April 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HERON THERAPEUTICS, INC. /DE/
Report date April 13, 2023 · Filed April 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,648 |
Ending reported balance
After 2023-04-13 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2023-04-13 · Exercise / conversion · Acquired 1,250 · Balance 44,096 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2023-04-13 · Exercise / conversion · Acquired 4,564 · Balance 48,660 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 3 · 2023-04-13 · Tax withholding · Disposed 2,012 · Balance 46,648 F2: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 7,500 |
Reported balance
After 2023-04-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-04-13 · Exercise / conversion · Disposed 1,250 · Balance 7,500 F1: Restricted stock units convert into common stock on a one-for-one basis. F3: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 27,936 |
Reported balance
After 2023-04-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-04-13 · Exercise / conversion · Disposed 4,564 · Balance 27,936 F1: Restricted stock units convert into common stock on a one-for-one basis. F4: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.
F3: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).
F4: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SENOMYX INC
Report date November 02, 2018 · Filed November 02, 2018
Section 16 reporting ended · disclosed 2018-11-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-11-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-11-02 · Other · Disposed 111,469 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any applicable withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3: Prior reports erroneously reflected all shares as indirectly held by trust, when a portion of the shares were actually directly held by the insider as reflected herein. |
| Common StockSEC Table I · non-derivative | IndirectBy family trust | 0 |
Reported balance
After 2018-11-02 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-11-02 · Other · Disposed 108,293 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). F4: Includes 25,772 shares of Common Stock that were acquired by the Reporting Person on 8/31/18 pursuant to the Issuer's Employee Stock Purchase Plan. F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any applicable withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3: Prior reports erroneously reflected all shares as indirectly held by trust, when a portion of the shares were actually directly held by the insider as reflected herein. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2027-03-14 | Direct | 0 |
Reported balance
After 2018-11-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-11-02 · Disposition to issuer · Disposed 417,000 · Balance 0 F5: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 · Expires 2028-03-14 | Direct | 0 |
Reported balance
After 2018-11-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-11-02 · Disposition to issuer · Disposed 363,000 · Balance 0 F5: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").
F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any applicable withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger").
F3: Prior reports erroneously reflected all shares as indirectly held by trust, when a portion of the shares were actually directly held by the insider as reflected herein.
F4: Includes 25,772 shares of Common Stock that were acquired by the Reporting Person on 8/31/18 pursuant to the Issuer's Employee Stock Purchase Plan.
F5: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 13, 2023 Filed Apr 17, 2023 21:27 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 4,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024499 · doc4.xml · derivative · entry 5 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,936 Underlying: Common Stock · 4,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document |
| April 13, 2023 Filed Apr 17, 2023 21:27 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024499 · doc4.xml · derivative · entry 4 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| April 13, 2023 Filed Apr 17, 2023 21:27 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 2,012 | $2.88 | $5,794.56 |
DisclosureSEC source: 0001209191-23-024499 · doc4.xml · nonDerivative · entry 3 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,648 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| April 13, 2023 Filed Apr 17, 2023 21:27 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 4,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-024499 · doc4.xml · nonDerivative · entry 2 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 13, 2023 Filed Apr 17, 2023 21:27 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-024499 · doc4.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 22:09 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantPerformance Stock Units · Derivative | 66,385 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004302 · doc4.xml · derivative · entry 1 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,385 Underlying: Common Stock · 66,385 shares Expires not disclosed F1 · derivative.exercise_date: On July 25, 2022, the Compensation Committee of the Issuer (the "Committee") granted the Reporting Person Performance Stock Units ("PSUs"), the vesting of which was subject to the achievement of certain corporate performance goals and time-based vesting. On January 18, 2023, the Committee determined that certain performance goals of the PSUs had been achieved. The PSUs are further subject to a time-based vesting schedule. The PSUs will vest in full on the first anniversary of the grant date subject to continued employment through such date. Upon vesting and settlement of the PSUs, the Reporting Person will receive a number of shares of common stock of the Issuer equal to the number of PSUs that have vested. F1 · derivative.expiration_date: On July 25, 2022, the Compensation Committee of the Issuer (the "Committee") granted the Reporting Person Performance Stock Units ("PSUs"), the vesting of which was subject to the achievement of certain corporate performance goals and time-based vesting. On January 18, 2023, the Committee determined that certain performance goals of the PSUs had been achieved. The PSUs are further subject to a time-based vesting schedule. The PSUs will vest in full on the first anniversary of the grant date subject to continued employment through such date. Upon vesting and settlement of the PSUs, the Reporting Person will receive a number of shares of common stock of the Issuer equal to the number of PSUs that have vested. Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 22:36 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 4,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003562 · doc4.xml · derivative · entry 5 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 4,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 22:36 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003562 · doc4.xml · derivative · entry 4 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 22:36 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 2,012 | $3.17 | $6,378.04 |
DisclosureSEC source: 0001209191-23-003562 · doc4.xml · nonDerivative · entry 3 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,846 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 22:36 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 4,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-003562 · doc4.xml · nonDerivative · entry 2 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 22:36 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-003562 · doc4.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:37 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 4,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-053834 · doc4.xml · derivative · entry 5 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,064 Underlying: Common Stock · 4,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:37 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-053834 · doc4.xml · derivative · entry 4 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:37 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 2,012 | $3.76 | $7,565.12 |
DisclosureSEC source: 0001209191-22-053834 · doc4.xml · nonDerivative · entry 3 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,044 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:37 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 4,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-053834 · doc4.xml · nonDerivative · entry 2 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:37 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-053834 · doc4.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 22:22 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 165,961 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001209191-22-043291 · doc4.xml · derivative · entry 1 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,961 Underlying: Common Stock · 165,961 shares Expires 2032-07-25 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 8 equal quarterly installments beginning one quarter after the date of grant (07/25/2022). Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:56 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 4,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042261 · doc4.xml · derivative · entry 5 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,628 Underlying: Common Stock · 4,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:56 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042261 · doc4.xml · derivative · entry 4 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:56 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 2,012 | $3.01 | $6,056.12 |
DisclosureSEC source: 0001209191-22-042261 · doc4.xml · nonDerivative · entry 3 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,242 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:56 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 4,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-042261 · doc4.xml · nonDerivative · entry 2 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:56 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-042261 · doc4.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 21:04 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 4,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-024521 · doc4.xml · derivative · entry 5 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,192 Underlying: Common Stock · 4,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 21:04 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-024521 · doc4.xml · derivative · entry 4 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 21:04 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 2,012 | $6.07 | $12,212.84 |
DisclosureSEC source: 0001209191-22-024521 · doc4.xml · nonDerivative · entry 3 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,440 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 21:04 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 4,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-024521 · doc4.xml · nonDerivative · entry 2 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 21:04 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-024521 · doc4.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:07 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 4,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003361 · doc4.xml · derivative · entry 5 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,756 Underlying: Common Stock · 4,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant. F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant. Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:07 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003361 · doc4.xml · derivative · entry 4 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:07 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 2,012 | $8.30 | $16,699.60 |
DisclosureSEC source: 0001209191-22-003361 · doc4.xml · nonDerivative · entry 3 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,638 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:07 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 4,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-003361 · doc4.xml · nonDerivative · entry 2 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:07 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-003361 · doc4.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 29, 2021 Filed Dec 23, 2021 23:59 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | OtherCommon Stock | 817 | $9.36 | $7,645.89 |
DisclosureSEC source: 0001209191-21-071173 · doc4.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,836 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on October 29, 2021. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:24 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantRestricted Stock Units · Derivative | 55,320 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060550 · doc4.xml · derivative · entry 5 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,320 Underlying: Common Stock · 55,320 shares Expires not disclosed F5 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant. F5 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:24 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 92,200 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001209191-21-060550 · doc4.xml · derivative · entry 4 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,200 Underlying: Common Stock · 92,200 shares Expires 2031-10-13 F4 · derivative.exercise_date: The stock option vests and becomes exercisable monthly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that the stock option will be fully vested on the four year anniversary of the date of grant. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:24 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060550 · doc4.xml · derivative · entry 3 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:24 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 433 | $10.55 | $4,568.15 |
DisclosureSEC source: 0001209191-21-060550 · doc4.xml · nonDerivative · entry 2 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,019 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:24 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-060550 · doc4.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 20:49 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-046789 · doc4.xml · derivative · entry 4 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,250 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). F4 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 20:49 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 433 | $13.48 | $5,836.84 |
DisclosureSEC source: 0001209191-21-046789 · doc4.xml · nonDerivative · entry 3 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,202 F3 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 20:49 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046789 · doc4.xml · nonDerivative · entry 2 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 30, 2021 Filed Jul 15, 2021 20:49 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | OtherCommon Stock | 971 | $13.90 | $13,494.47 |
DisclosureSEC source: 0001209191-21-046789 · doc4.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,385 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2021. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:53 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026843 · doc4.xml · derivative · entry 3 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:53 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 433 | $16.66 | $7,213.78 |
DisclosureSEC source: 0001209191-21-026843 · doc4.xml · nonDerivative · entry 2 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,414 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:53 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-026843 · doc4.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:27 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-003798 · doc4.xml · derivative · entry 3 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:27 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 433 | $18.16 | $7,863.28 |
DisclosureSEC source: 0001209191-21-003798 · doc4.xml · nonDerivative · entry 2 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,597 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:27 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-003798 · doc4.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 30, 2020 Filed Dec 23, 2020 21:24 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | OtherCommon Stock | 637 | $11.65 | $7,423.28 |
DisclosureSEC source: 0001209191-20-065016 · doc4.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,780 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on October 30, 2020. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:24 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054908 · doc4.xml · derivative · entry 2 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant. F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.